Shenzhou NeuroTech Secures Tens of Millions in Series A Funding Led by Boyuan Capital

VCBeat (WeChat: vcbeat) learned第一时间that recently, SNEURO MEDICAL, an innovative company in the field of neuromodulation in China, has completed a multi-million yuan A round of financing, led by Boyuan Capital.This round of financing will be used for the research and development, clinical trials and registration, market expansion, and team expansion of SNEURO MEDICAL's neuromodulation products, thereby accelerating the company's development in the neuromodulation field.。This round of financing also marks the company's recognition by professional investment institutions once again since the completion of the Pre-A round in September.

SNEURO MEDICAL is dedicated to the independent research, development, and production of medical devices in the fields of implantable neurostimulation and brain-computer interfaces, continuously providing doctors and patients with more advanced and effective treatment options, and improving the quality of life for more patients with neurological disorders.

The company is a high-tech enterprise jointly established by a team with rich experience in the research and development of implantable medical devices in the field of neurostimulation, several returned doctors from overseas in the fields of chips and radio frequency, renowned American experts in pain medicine, an expert team from the Pain Department of the First Affiliated Hospital of Zhejiang University School of Medicine, and various professionals. The company has built a nearly 1,000-square-meter GMP workshop of 100,000-grade and a biochemical laboratory of 10,000-grade. Bearing a mission and carrying dreams, the company adheres to the goal of innovating neuromodulation products. Relying on domestic and international talent and technical advantages, it continuously grows and develops in the field of neuromodulation with innovative medical technology and meticulously crafted product quality.

Since its registration and establishment in December 2018, the company has owned nearly thirty patented technologies with full independent intellectual property rights. It has successfully developed products such as the Spinal Cord Stimulator (SCS) and short-term implantable Peripheral Nerve Stimulator (PNS), which can effectively treat refractory pain. In the future, it will also cover various fully implantable peripheral nerve stimulators, autonomic nerve stimulators, and other fields to improve the quality of life for patients suffering from pain, urinary incontinence, heart failure, hypertension, sleep apnea, and more, making a positive contribution to the development of the neuromodulation industry. Among these, the 2022 "Pioneer" and "Leader" R&D project of the Zhejiang Provincial Department of Science and Technology, conducted in collaboration with the First Affiliated Hospital of Zhejiang University, has passed public announcement and received millions of yuan in provincial financial subsidies.

Boyu Capital Investment Vice President An'an Wu stated:"As a startup, the company's excellent competitiveness in product development, construction, and management of the neuromodulation field has left a deep impression on us, offering new business opportunities in this area. Boyuan is optimistic about this entirely new competitive potential and will accompany the enterprise for the long term to grow into a leading company in the neuromodulation field."

SNEURO MEDICAL founder Wang Shoudong also stated:"In the future, SNEURO MEDICAL will continue to focus on the research and development of neuromodulation products. It will also expand into areas such as autonomic nerve stimulators and peripheral nerve stimulators, thereby establishing a complete line of neuromodulation products. We will continue to improve and strengthen our foundation in innovative R&D. We thank Boyuan Capital for recognizing SNEURO MEDICAL, which allows us to accelerate the launch of various neuromodulation products. We look forward to working with Boyuan Capital to benefit more patients and create greater value for society!"

Founded in 2017, it is a professional investment institution focused on investing in and incubating outstanding healthcare startups in the Chinese market. We are not only investors, but also long-term partners of entrepreneurs. We consistently support the most exceptional healthcare entrepreneurs in building the next generation of leading enterprises in China's healthcare industry.